Cabel

    Now that the Diamond Study cat is out of the bag we have an educated guess as to the incremental increase in event rates in low Hdl group. I only used half of the increase or approx 2%; its actually very close to 4% . If we use the full 4 % the ratio goes to 12 to 2 ! If standard of care lowers both placebo and on drug groups rates seen in Examine of 8% then the low Hdl incremental increase becomes a even greater factor in our favor . I believe as this Diamond Study data is fairly reviewed the share price will be re rated significantly higher. I have no idea why no Analyst has picked up on this and the Company silent ?